Virus injection takes on tough pancreatic cancer
NCT ID NCT07006077
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment called hV01, a virus modified to attack cancer cells and boost the immune system. It is for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to see if the virus can shrink tumors and control the disease, while also checking for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hangzhou First People's Hospital,School of Medicine,Westlake University
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody slow advanced pancreatic cancer?
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
- Experimental combo targets Hard-to-Treat pancreatic cancer
- Engineered immune cells take aim at a common pancreatic cancer mutation
- Radioactive injection takes on tough pancreatic cancer in early trial